[
  {
    "drug_id": "D413D3EC269",
    "canonical_name": "medi6570",
    "gate_decision": "NO-GO",
    "gate_reasons": [
      "pmids<3"
    ],
    "scores": {
      "evidence_strength_0_30": 8.1,
      "mechanism_plausibility_0_20": 14.0,
      "translatability_0_20": 6.0,
      "safety_fit_0_20": 20.0,
      "practicality_0_10": 1.0,
      "total_score_0_100": 49.1
    },
    "evidence_summary": {
      "benefit": 2,
      "harm": 0,
      "neutral": 0,
      "unknown": 0,
      "total_pmids": 2
    },
    "key_pmids": [
      "36688371",
      "40999229"
    ],
    "mechanism_hypothesis": "Medi6570 may reduce atherosclerosis through anti-inflammatory effects. Based on 2 supporting publications, the drug shows potential benefit in preclinical and/or clinical studies.",
    "next_steps": [
      "❌ Do not advance to validation at this time",
      "Limited literature - may indicate insufficient research interest",
      "Archive dossier for future reference"
    ],
    "dossier_path": "output/step6_simple/dossiers/D413D3EC269__medi6570.json"
  },
  {
    "drug_id": "D4BE4598792",
    "canonical_name": "apolipoprotein a-i human apoa-i",
    "gate_decision": "NO-GO",
    "gate_reasons": [
      "safety_concern"
    ],
    "scores": {
      "evidence_strength_0_30": 26.7,
      "mechanism_plausibility_0_20": 17.3,
      "translatability_0_20": 20.0,
      "safety_fit_0_20": 12.0,
      "practicality_0_10": 8.0,
      "total_score_0_100": 84.0
    },
    "evidence_summary": {
      "benefit": 12,
      "harm": 6,
      "neutral": 0,
      "unknown": 2,
      "total_pmids": 80
    },
    "key_pmids": [
      "31567014",
      "18287885",
      "28069582",
      "28939717",
      "40263360",
      "17430166",
      "35120132",
      "16285990",
      "40371638",
      "26681753"
    ],
    "mechanism_hypothesis": "Apolipoprotein A-I Human Apoa-I may reduce atherosclerosis through anti-inflammatory effects, plaque stabilization/regression. Based on 12 supporting publications, the drug shows potential benefit in preclinical and/or clinical studies.",
    "next_steps": [
      "❌ Do not advance to validation at this time",
      "Archive dossier for future reference"
    ],
    "dossier_path": "output/step6_simple/dossiers/D4BE4598792__apolipoprotein_a-i_human_apoa-i.json"
  },
  {
    "drug_id": "D4BE4598792",
    "canonical_name": "apolipoprotein a-i human apoa-i",
    "gate_decision": "NO-GO",
    "gate_reasons": [
      "safety_concern"
    ],
    "scores": {
      "evidence_strength_0_30": 23.7,
      "mechanism_plausibility_0_20": 14.7,
      "translatability_0_20": 18.0,
      "safety_fit_0_20": 12.0,
      "practicality_0_10": 6.0,
      "total_score_0_100": 74.4
    },
    "evidence_summary": {
      "benefit": 10,
      "harm": 7,
      "neutral": 0,
      "unknown": 3,
      "total_pmids": 20
    },
    "key_pmids": [
      "35120132",
      "33861588",
      "28069582",
      "24407029",
      "29437574",
      "39643078",
      "40371638",
      "40263360",
      "20425244",
      "18287885"
    ],
    "mechanism_hypothesis": "Apolipoprotein A-I Human Apoa-I may reduce atherosclerosis through anti-inflammatory effects, antioxidant activity, lipid modulation. Based on 10 supporting publications, the drug shows potential benefit in preclinical and/or clinical studies.",
    "next_steps": [
      "❌ Do not advance to validation at this time",
      "Archive dossier for future reference"
    ],
    "dossier_path": "output/step6_simple/dossiers/D4BE4598792__apolipoprotein_a-i_human_apoa-i_embed.json"
  },
  {
    "drug_id": "D81B744A593",
    "canonical_name": "resveratrol",
    "gate_decision": "GO",
    "gate_reasons": [],
    "scores": {
      "evidence_strength_0_30": 30.0,
      "mechanism_plausibility_0_20": 20.0,
      "translatability_0_20": 20.0,
      "safety_fit_0_20": 20.0,
      "practicality_0_10": 8.0,
      "total_score_0_100": 98.0
    },
    "evidence_summary": {
      "benefit": 17,
      "harm": 0,
      "neutral": 0,
      "unknown": 3,
      "total_pmids": 80
    },
    "key_pmids": [
      "40043912",
      "24895526",
      "27156686",
      "30885430",
      "26306466",
      "40634132",
      "37030661",
      "23450206",
      "23337345",
      "36932392"
    ],
    "mechanism_hypothesis": "Resveratrol may reduce atherosclerosis through anti-inflammatory effects, lipid modulation, macrophage modulation. Based on 17 supporting publications, the drug shows potential benefit in preclinical and/or clinical studies.",
    "next_steps": [
      "✅ Proceed to detailed validation planning",
      "Review full evidence dossier and identify key mechanistic papers",
      "Design preclinical validation experiments (if mechanism unclear)",
      "Evaluate clinical trial feasibility and endpoints",
      "Assess drug availability and regulatory pathway"
    ],
    "dossier_path": "output/step6_simple/dossiers/D81B744A593__resveratrol.json"
  },
  {
    "drug_id": "D8291C5A5C4",
    "canonical_name": "nicotinamide riboside",
    "gate_decision": "MAYBE",
    "gate_reasons": [
      "score<60.0"
    ],
    "scores": {
      "evidence_strength_0_30": 13.4,
      "mechanism_plausibility_0_20": 13.7,
      "translatability_0_20": 12.0,
      "safety_fit_0_20": 16.0,
      "practicality_0_10": 4.0,
      "total_score_0_100": 59.1
    },
    "evidence_summary": {
      "benefit": 5,
      "harm": 2,
      "neutral": 0,
      "unknown": 4,
      "total_pmids": 11
    },
    "key_pmids": [
      "38871717",
      "39034866",
      "35196876",
      "40257024",
      "32758058"
    ],
    "mechanism_hypothesis": "Nicotinamide Riboside shows evidence of benefit in 5 publications. Specific mechanism requires further investigation of literature.",
    "next_steps": [
      "⚠️ Borderline candidate - requires additional evidence review",
      "Manual review of top 20 papers to confirm benefit/harm classification",
      "Search for additional evidence (expanded PubMed queries)",
      "Gather more evidence - current coverage may be insufficient",
      "Re-score after evidence review to determine GO/NO-GO"
    ],
    "dossier_path": "output/step6_simple/dossiers/D8291C5A5C4__nicotinamide_riboside.json"
  },
  {
    "drug_id": "D9F9BB8C160",
    "canonical_name": "creatine monohydrate",
    "gate_decision": "NO-GO",
    "gate_reasons": [
      "benefit<2",
      "pmids<3"
    ],
    "scores": {
      "evidence_strength_0_30": 0.1,
      "mechanism_plausibility_0_20": 6.0,
      "translatability_0_20": 4.0,
      "safety_fit_0_20": 20.0,
      "practicality_0_10": 1.0,
      "total_score_0_100": 31.1
    },
    "evidence_summary": {
      "benefit": 0,
      "harm": 0,
      "neutral": 0,
      "unknown": 2,
      "total_pmids": 2
    },
    "key_pmids": [],
    "mechanism_hypothesis": "Limited evidence available for creatine monohydrate in atherosclerosis. Mechanism unclear.",
    "next_steps": [
      "❌ Do not advance to validation at this time",
      "Insufficient benefit evidence - consider removing from pipeline",
      "Limited literature - may indicate insufficient research interest",
      "Archive dossier for future reference"
    ],
    "dossier_path": "output/step6_simple/dossiers/D9F9BB8C160__creatine_monohydrate.json"
  },
  {
    "drug_id": "DD76A1941B2",
    "canonical_name": "dexamethasone",
    "gate_decision": "GO",
    "gate_reasons": [],
    "scores": {
      "evidence_strength_0_30": 30.0,
      "mechanism_plausibility_0_20": 20.0,
      "translatability_0_20": 20.0,
      "safety_fit_0_20": 16.0,
      "practicality_0_10": 8.0,
      "total_score_0_100": 94.0
    },
    "evidence_summary": {
      "benefit": 18,
      "harm": 0,
      "neutral": 0,
      "unknown": 2,
      "total_pmids": 80
    },
    "key_pmids": [
      "8499410",
      "40239267",
      "16815711",
      "30478968",
      "34784501",
      "25735629",
      "1453236",
      "25874855",
      "24899497",
      "33187578"
    ],
    "mechanism_hypothesis": "Dexamethasone may reduce atherosclerosis through anti-inflammatory effects, lipid modulation, macrophage modulation, plaque stabilization/regression. Based on 18 supporting publications, the drug shows potential benefit in preclinical and/or clinical studies.",
    "next_steps": [
      "✅ Proceed to detailed validation planning",
      "Review full evidence dossier and identify key mechanistic papers",
      "Design preclinical validation experiments (if mechanism unclear)",
      "Evaluate clinical trial feasibility and endpoints",
      "Assess drug availability and regulatory pathway"
    ],
    "dossier_path": "output/step6_simple/dossiers/DD76A1941B2__dexamethasone.json"
  },
  {
    "drug_id": "DF09C894FE9",
    "canonical_name": "vm202",
    "gate_decision": "NO-GO",
    "gate_reasons": [
      "benefit<2",
      "pmids<3"
    ],
    "scores": {
      "evidence_strength_0_30": 4.1,
      "mechanism_plausibility_0_20": 14.0,
      "translatability_0_20": 4.0,
      "safety_fit_0_20": 20.0,
      "practicality_0_10": 1.0,
      "total_score_0_100": 43.1
    },
    "evidence_summary": {
      "benefit": 1,
      "harm": 0,
      "neutral": 0,
      "unknown": 1,
      "total_pmids": 2
    },
    "key_pmids": [
      "21430785"
    ],
    "mechanism_hypothesis": "Vm202 shows evidence of benefit in 1 publications. Specific mechanism requires further investigation of literature.",
    "next_steps": [
      "❌ Do not advance to validation at this time",
      "Insufficient benefit evidence - consider removing from pipeline",
      "Limited literature - may indicate insufficient research interest",
      "Archive dossier for future reference"
    ],
    "dossier_path": "output/step6_simple/dossiers/DF09C894FE9__vm202.json"
  }
]